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model from the perspective of a US private insurance payer to evaluate the cost-
effectiveness of rituximab, tacrolimus, and cyclosporine in a hypothetical cohort 
of 1,000 patients with refractory MG, aged 20 years and above. We obtained dis-
ease transition probabilities, costs and outcomes data from the published litera-
ture. We calculated the incremental cost-effectiveness ratios (ICERs) as cost per 
quality-adjusted life-year (QALY) gained and cost per myasthenic crisis averted 
after the first two years of treatment and over a patient’s lifetime. RESULTS: In 
the first two years after treatment rituximab is not cost-effective compared with 
cyclosporine, given an ICER of $368,823 per QALY gained. However, over a patient’s 
lifetime rituximab has an ICER of $41,947 per QALY gained making it more cost-
effective than cyclosporine in the context of the commonly accepted US thresh-
old of $50,000 per QALY gained. Tacrolimus is more costly and less effective 
than cyclosporine and rituximab both after two years of treatment and over a 
 patient’s lifetime. CONCLUSIONS: Assuming the benefits of treatment persist over 
time, rituximab is more cost-effective than cyclosporine over a patient’s lifetime but 
not after two years of treatment under both the standard US threshold of $50,000 
per QALY gained and an alternative higher threshold of $100,000 per QALY gained. 
Additional research is needed to evaluate the long-term benefits of rituximab.
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OBJECTIVES: Nearly 54 million Medicare beneficiaries, the overwhelming majority 
of whom are 65 plus years of age, reside in the US. Many beneficiaries suffer from 
chronic pain and need to use opioid analgesics for treatment. Medicare Part D is 
the outpatient prescription drug benefit available to beneficiaries through private 
insurance companies. Plan offerings differ across the country and each plan can 
have a different cost-sharing structure and formulary. We sought to examine the 
cost differences between therapeutically equivalent doses of opioid analgesics 
across all Medicare Part D Stand-alone prescription drug plans (PDPs). METHODS: 
Five short- and five long-acting opioid analgesic drugs were selected based on 
their prevalence of use and effectiveness at treating chronic pain. Therapeutically 
equivalent doses of each drug were entered into the Medicare Plan Finder Tool 
(www.medicare.gov) and 2015 data from 965 PDPs in 34 Medicare regions across the 
country were recorded. Collected data for each drug included: full cost, expected 
out-of-pocket costs both in a retail and mail order setting, and cost at a stand-
ard and preferred network pharmacy. RESULTS: Full annual retail drug costs var-
ied from a low of $134.42 (Methadone 5mg; thrice daily) to a high of $10,443.30 
(Hydromorphone ER 16mg; once daily). Beneficiary cost-sharing of the full annual 
drug costs in a retail pharmacy ranged from 36% (Hydrocodone 5/325; 12 tabs daily) 
to 93% (Hydromorphone ER). The annual out-of-pocket costs through mail order 
were between 88% (Oxycodone 5mg; 8 tabs daily) and 102% (Morphine 30mg; 2 
tabs daily) of the costs in a retail pharmacy setting. Beneficiary out-of-pocket costs 
for the same drug was between 7% and 44% cheaper at a preferred network phar-
macy as compared to a standard network pharmacy. CONCLUSIONS: Considerable 
cost variability exists among equipotent opioid analgesics across Medicare PDPs. 
Minimizing beneficiary out-of-pocket costs may improve economic outcomes with-
out sacrificing clinical outcomes.
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OBJECTIVES: Ivacaftor is a breakthrough treatment for cystic fibrosis (CF) patients 
with the G551D genetic mutation. Clinical trials show ivacaftor significantly 
improves lung function. Information on lifetime clinical effects and cost are lacking. 
This study aims to forecast lifetime outcomes and cost by comparing ivacaftor plus 
usual care versus usual care alone. METHODS: A lifetime Markov model of ivacaftor 
for G551D mutation CF patients aged ≥ 6 years was conducted from a United States 
payer perspective. The model consisted of 5 health states: 1) forced expiratory vol-
ume 1-second (FEV1) % predicted > 70%, 2) 40%≤ FEV1≤ 70%, 3) FEV1< 40%, 4) Lung 
transplantation, and 5) Death. All inputs were determined by literature sources. 
Efficacy of ivacaftor was from previous randomized clinical trials for the first 2 years. 
The efficacy after 2 years was assumed half of the observed efficacy (consistent 
with United Kingdom assessment assumption). The budget impact was estimated. 
We indirectly estimated ivacaftor’s improvement in CF outcome gaps compared 
to the non-CF population. RESULTS: Compared to the usual care alone, ivacaftor 
treatment was associated with 18.09 additional life-years [(95% credible interval 
(CI); 14.63-21.13] and 14.92 additional quality-adjusted life-years (QALYs) [95%CI; 
11.92 – 17.95] over an average lifetime. Moving from usual care alone to ivacaftor 
treatment was associated with reducing the survival and QALY gaps of the non-CF 
population by 52.32% and 44.29%, respectively. The incremental lifetime cost with 
3% discount was $3,740,480. The budget impact was $0.09 per-member per-month 
[95% CI; $0.07 to $0.11]. CONCLUSIONS: Ivacaftor was forecasted to increase life-
years and QALYs in CF patients with the G551D mutation and move morbidity 
and mortality outcomes closer to that of their non-CF peers. The overall cost in 
patients with ivacaftor is much higher than usual care, but comes at a relatively low 
budget impact. Uncertainty in this literature-informed analysis could be reduced 
with patient-level analyses.
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sensitivity analyses indicates that for these comparisons, based on a threshold of 
£20,000, Movantik has a respective probability of 91%, 83% and 100% of being cost 
effective. In a population of LIR patients who are taking step 3 opioids, Movantik is 
dominant vs. Targin over a 5 year time horizon. CONCLUSIONS: Movantik is a cost-
effective treatment option for patients with OIC who have experienced inadequate 
response to laxative(s).
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OBJECTIVES: Limbal Stem Cell Deficiency (LSCD) is a rare condition characterized by 
the shortage of limbal stem cells in the eye resulting in corneal conjunctivalization, 
corneal opacity, visual impairment and even blindness. Recently, the first advanced 
therapy medicinal product (ATMP) containing stem cells (GPLSCD01) has been rec-
ommended for approval by EMA in moderate-severe LSCD due to chemical or physi-
cal burn. A Cost Effectiveness Analysis (CEA) was performed, from a public payer 
perspective, to compare GPLSCD01 in LSCD with conservative treatment, given that, 
currently, no other medicinal product is approved for this disease. METHODS: We 
analyzed visual acuity and symptoms from 99 patients (average age 46.8 yrs.) treated 
with GPLSCD01; data were taken from a retrospective, case-series, non-randomized, 
non-controlled, multicenter clinical study (HLSTM01), covering up to 10 years fol-
low-up. LSCD-impaired visual acuity and symptoms such as pain, burning and 
photophobia were used in the model to assess the QoL associated with the condi-
tion, and Quality Adjusted Life Years (QALY) to compare the outcomes of GPLSCD01 
treatment versus conservative management, in a similar patient pool. RESULTS: 
Patients under conservative treatment had between 10.29 and 17.24 QALYs, depend-
ing on LSCD severity, whereas patients treated with GPLSCD01 showed between 
15.93 and 22.49 QALYs, with a total utility gain between 5.25 and 6.04 QALYs in the 
GPLSCD01 group, this result being already discounted by 3.0%, in compliance with 
National Institute for Health Care Excellence (NICE) guidelines. Due to the utility 
gain, GPLSCD01 would meet NICE conventional ICER thresholds (20,000 – 30,000 GBP/
QALY) up to a treatment cost of 150,000 GBP. CONCLUSIONS: GPLSCD01 is a regen-
erative medicine, offering long-term, potentially life-long effectiveness after single 
administration. This CEA shows that GPLSCD01 in moderate-severe LSCD provides a 
significant gain in QALYs compared to conventional, conservative management of 
the condition, balancing, from a payer perspective, initial higher acquisition costs.
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OBJECTIVES: The cost of lost productivity associated with chronic fatigue has 
been estimated to be more than £75 million per year in the U.K. Cognitive behav-
ioral Therapy (CBT) based fatigue self-management (FSM) has been shown to 
be effective in reducing fatigue symptoms. This study aimed to examine the 
cost-effectiveness of a home-based CBT-FSM intervention as compared to usual 
care. METHODS: 137 Primary care patients between 18 and 65 years of aging who 
had at least six months of persistent fatigue were randomized into either home-
based CBT-FSM intervention (n= 89, 45 with actigraph and web diaries and 44 with 
pedometer and paper diaries) or usual care (n= 48). All patients were followed for 12 
months post-treatment. Effectiveness was measured by the Fatigue Severity Scale 
(FSS) and health care resource use was measured by a utilization diary. Resource 
use categories included provider visits, diagnostic tests, prescription medication 
use, and use of emergency room, hospital, informal care, and days of lost work. We 
used ordinary least squares model and generalized linear model to estimate the 
treatment effect on effectiveness and health care expenditures, respectively. Cost-
effectiveness was measured by the incremental cost-effectiveness ratio (ICER) and 
net monetary benefit. RESULTS: The sample had a mean age of 48.5 years and 
most patients were female (88.3%). Baseline characteristics were similar between 
the intervention and control groups. Adjusting for baseline characteristics, the 
intervention had a small non-significant effect on FSS (-0.16, p= 0.32) and total 
expenditures (0.09, p= 0.32), resulting an ICER of 388 (bootstrapped 95% CI: -16463, 
17239). Cost-effectiveness acceptability curve showed that CBT-FSM had an 85% 
probability of being cost-effective if societal willingness-to-pay for each 1 point 
reduction on the FSS. CONCLUSIONS: The intervention did not appear to be cost-
effective as compared to usual care. The home-based intervention needs to be 
modified to maintain effectiveness achieved in prior interventions delivered by 
training professionals.
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OBJECTIVES: Myasthenia gravis (MG) is a rare autoimmune disorder characterized 
by exacerbations and remissions. The costs of managing MG are higher than those 
of many other chronic neurological diseases and there are no studies evaluating 
the cost-effectiveness of treatment alternatives for refractory MG in patients who 
failed to respond to at least two successive immunosuppressive drugs. This study 
aimed to assess the incremental costs and benefits of rituximab, cyclosporine, 
and tacrolimus in the treatment of refractory MG. METHODS: We used a Markov 
